A single shot against Ebola and Marburg virus

@article{Baize2005ASS,
  title={A single shot against Ebola and Marburg virus},
  author={Sylvain Baize},
  journal={Nature Medicine},
  year={2005},
  volume={11},
  pages={720-721}
}
  • S. Baize
  • Published 1 July 2005
  • Medicine
  • Nature Medicine
New vaccines protect monkeys from Ebola and Marburg virus infections after a single shot. The live vaccines are built using a virus platform that should allow widespread protection in people, if the approach holds up in later safety and efficacy studies (pages 786–790). 
Progress in filovirus vaccine development: evaluating the potential for clinical use
TLDR
The results demonstrate that achieving a vaccine that is protective against filoviruses is possible; the challenge now is to prove its safety and efficacy in order to obtain a vaccines that is ready for human use.
[Ebola and Marburg viruses: the humans strike back].
TLDR
The mechanism by which Ebola GP is converted to a fusion-active form is elucidated, thus opening new therapeutic approaches options, and Jones SM et al. have successfully vaccinated monkeys with recombinant vesicular stomatitis virus expressing Ebola or Marburg virus surface glycoprotein GP, a promising vaccine approach.
VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.
TLDR
The VSVΔG/EBOV GP vaccine has provided 100% protection in the mouse, guineas and humans against Zaire ebolavirus.
VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.
TLDR
Data suggest that NK cells play an important role in VSVΔG/EBOV GP-induced protection of EBOV by increasing NK cytotoxicity, and IFN-γ secretion.
Dynamic blood single-cell immune responses in patients with COVID-19
TLDR
TCR and BCR sequences analyses indicated that patients with CO VID-19 developed specific immune responses against SARS-CoV-2 antigens, suggesting the important role of the IFN-I pathway in the immune response of COVID-19.
Un vaccin contre les virus Ebola et Marburg : des résultats prometteurs
TLDR
Le virus Marburg (Marv), les resultats les plus encourageants ont ete obtenus dans un modele simien avec un vaccin exprimant the glycoproteine d’enveloppe par l’intermediaire d‘un alphavirus.
Ebola et Marburg : les hommes contre-attaquent
TLDR
La frequence des epidemies de fievres hemorragiques a virus Ebola ou Marburg constatee en Afrique Centrale est en augmentation depuis une dizaine d’annees, mais une quarantaine stricte reste le seul moyen de lutter contre ces virus.
Viral haemorrhagic fevers caused by Lassa, Ebola and Marburg viruses.
  • N. Curtis
  • Medicine
    Advances in experimental medicine and biology
  • 2006

References

SHOWING 1-10 OF 11 REFERENCES
Ebola virus: from discovery to vaccine
TLDR
Insight into the ecology, immunology and pathogenesis of Ebola virus will promote the delivery of urgently required tools for rapid diagnostics, new antiviral agents and protective vaccines.
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
TLDR
The data suggest that these replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors are safe and highly efficacious in a relevant animal model.
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
TLDR
The development of accelerated vaccination against Ebola virus in non-human primates provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses.
Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
TLDR
The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms.
Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.
TLDR
An RNA replicon, based upon Venezuelan equine encephalitis (VEE) virus, was used as a vaccine vector; the VEE structural genes were replaced by genes for MBGV GP, nucleoprotein (NP), VP40, VP35, VP30, or VP24.
Multiple Ebola Virus Transmission Events and Rapid Decline of Central African Wildlife
TLDR
Recovered carcasses were infected by a variety of Ebola strains, suggesting that Ebola outbreaks in great apes result from multiple virus introductions from the natural host.
Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation.
TLDR
No serologic conversion was detected among contact persons in Côte d'Ivoire or Switzerland, suggesting that infection-control precautions were satisfactory, and a new subtype of Ebola was isolated from the patient's blood on days 4 and 8.
Highly Effective Control of an AIDS Virus Challenge in Macaques by Using Vesicular Stomatitis Virus and Modified Vaccinia Virus Ankara Vaccine Vectors in a Single-Boost Protocol
TLDR
Improved protection in MVA-boosted animals correlates with trends toward stronger prechallenge CD8+-T-cell responses to SHIV antigens and stronger postchallenge SHIV-neutralizing antibody production.
Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses
TLDR
The data suggest that the recombinant VSV can be used to study the role of the viral glycoproteins in virus replication, immune response, and pathogenesis and none of the rVSVs displayed pathogenic potential in animals.
Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995.
Ebola hemorrhagic fever (EHF) patients treated at Kikwit General Hospital during the 1995 outbreak were tested for viral antigen, IgG and IgM antibody, and infectious virus. Viral antigen could be
...
1
2
...